Foley Hoag Represents Dogma Therapeutics in Sale of Its Oral PCSK9 Inhibitor Program to AstraZeneca

Foley Hoag LLP represented Cambridge, MA-based Dogma Therapeutics in the sale of its oral PCSK9 program to global biopharmaceutical company AstraZeneca for upfront as well as downstream payments linked to global regulatory and commercial milestones. The ground-breaking project could prove transformational in the management of hypercholesterolemia and cardiovascular disease.  Dogma’s strategic goal in the sale to AstraZeneca is to accelerate access to patients unable to meet target LDL-C. 

Dogma has discovered small molecules that directly bind to a novel binding pocket in PCSK9. Guided by dozens of high-resolution x-ray structures of inhibitors bound to the PCSK9 protein, these molecules have allowed rapid optimization to picomolar affinity with exquisite physicochemical attributes and robust LDL-C lowering when dosed orally in preclinical models of hypercholesterolemia. 

Foley Hoag attorneys Hemmie Chang, Adrienne Ellman, David Halstead, Nicola Lemay, Kathryn Lumb, Laura Trumbull, Yuliya Kozachenko, Chasse Osborn and Kyrsten Lundh represented Dogma in the transaction.